InstalabLoading...
InstalabLoading...
Your standard heart health labs can come back perfect and still miss something that matters. The PHACTR1 variant (rs9349379) is a single letter change in your DNA that shifts your risk for several serious blood vessel diseases, and it does so in an unusual way: one version of the variant raises your risk for the kind of artery disease that causes heart attacks, while the other version raises your risk for a different set of conditions, including spontaneous tears in your coronary or neck arteries. No cholesterol test, blood pressure reading, or stress test will ever pick this up.
This is a genetic test, not a blood level. You carry two copies of every gene, one from each parent, so your result will be one of three genotypes: AA, AG, or GG. That result never changes. You test once, and you have the answer for life. What makes this variant unusual is that both versions carry distinct risks, just for different diseases.
The PHACTR1 gene (phosphatase and actin regulator 1) produces a protein found in the cells lining your blood vessels, in immune cells called macrophages that patrol your arteries, and in your brain. The protein helps regulate how blood vessel walls respond to stress, how immune cells clean up damage, and how arteries maintain their structure.
But the rs9349379 variant does something researchers did not expect. Instead of primarily affecting the PHACTR1 protein itself, this variant acts as a remote control switch for a different gene called EDN1, located about 600,000 DNA letters away. EDN1 produces endothelin-1, one of the most powerful blood vessel constricting signals in your body. The A version of the variant is linked to lower endothelin-1 production, while the G version is linked to higher levels. This single mechanism helps explain why the two versions of the variant push risk in opposite directions for different diseases.
If you carry one or two copies of the G allele, you have a modestly higher risk of developing the plaque buildup in your coronary arteries that leads to heart attacks. A systematic review pooling data from multiple studies found that each copy of the G allele raises the odds of coronary artery disease by about 15% (OR 1.15). For coronary artery calcium, a measure of plaque already forming in your arteries, the risk increase was about 22% per copy (OR 1.22).
The mechanism appears to involve several processes at once. The G allele is associated with lower levels of the PHACTR1 protein in macrophages, which impairs a cleanup process called efferocytosis, where macrophages remove dead cells from artery walls. When this cleanup fails, dead cell debris accumulates inside plaques, creating larger areas of instability (sometimes called necrotic cores) and thinner protective caps over the plaque surface. In a study using mice engineered to lack macrophage PHACTR1, plaques had significantly more necrosis and were more prone to rupture.
These are modest increases in risk per allele, comparable to many other common genetic variants for heart disease. On their own, they do not predict who will or will not have a heart attack. But when combined with your other risk factors, including other genetic variants, lipid levels, blood pressure, and metabolic health, this information adds a layer of context that standard labs do not provide.
The A allele tells a very different story. It raises the risk for a group of conditions where arteries become structurally abnormal or tear spontaneously, without the typical plaque buildup seen in conventional heart disease.
There is a striking sex difference in who is affected. SCAD and FMD overwhelmingly affect women (about 80 to 90% of cases), while atherosclerotic coronary artery disease predominantly affects men. The same genetic locus contributes to both, through different mechanisms.
One of the most unusual features of this variant is its bidirectional risk profile. Carrying the G allele means higher risk for plaque-driven heart disease but lower risk for artery tears and FMD. Carrying the A allele flips that equation. This pattern, called pleiotropy (one gene affecting multiple traits), is uncommon in cardiovascular genetics and has practical implications for how you think about your result.
If your genotype is AG (one copy of each), you carry a modest increase in both directions. If you are AA, your atherosclerotic risk from this variant is lower, but your risk for non-atherosclerotic artery disease is higher. If you are GG, the reverse is true. Neither genotype is "safe" or "dangerous" in absolute terms. The value is in knowing which direction to watch more closely.
This is a common variant. The G allele is carried by roughly 36% of people of European ancestry, and population frequencies vary by ethnicity. Most people who carry the risk allele for any of these conditions will never develop that condition. The odds ratios are modest (1.15 to 1.67), meaning this variant shifts your probability, not your destiny.
This variant also operates independently of the traditional risk factors your doctor typically checks. Studies have confirmed that the association with coronary artery disease holds after adjusting for cholesterol, blood pressure, and diabetes. That independence is precisely why testing for it adds information: it captures vascular risk that lipid panels and metabolic labs cannot see.
Because this is a genetic test, your result is one of three fixed genotypes. There are no continuously variable "levels" and no universal risk tiers the way a cholesterol test has optimal and elevated ranges. Instead, each genotype carries a distinct risk profile based on research associations.
| Genotype | Atherosclerotic CAD Risk | SCAD / FMD / Dissection Risk | Endothelin-1 Tendency |
|---|---|---|---|
| AA | Lower (relative to G carriers) | Higher | Lower production |
| AG | Intermediate | Intermediate | Intermediate |
| GG | Higher | Lower | Higher production |
These risk profiles are drawn from genome-wide association studies and case-control research primarily in European-ancestry populations. The variant has also been studied in Chinese Han, Mexican, and Lebanese populations with similar directional findings, though exact odds ratios may differ across ancestries. Your result should be interpreted alongside your full personal and family history, not in isolation.
Most large studies of this variant have been conducted in European-ancestry populations. One study in Chinese Han participants found the GG genotype was specifically associated with increased coronary artery disease risk in women, a finding that differed from the male-predominant pattern seen in European cohorts. Studies in Mexican and Lebanese populations have confirmed the association with coronary artery disease, though the strength of the association varies.
If you belong to an ancestry group that has been less studied, the variant's risk estimates may be less precise for you. The direction of association (which allele raises which risk) appears consistent across populations, but the magnitude of risk may differ.
One study specifically examined this genetic region in people with familial hypercholesterolemia (FH), an inherited condition that causes very high LDL cholesterol from birth. In that population, carrying the protective allele at a linked variant (rs12526453) was associated with about a 50% reduction in coronary artery disease events. For people who already know they have FH, this variant may help distinguish who within that high-risk group faces the greatest danger and who may have some genetic protection.
Unlike biomarkers that fluctuate with diet, stress, illness, or medication, your genotype at this locus is fixed. You inherited it at conception, and it will never change. That means you only need to test once. There is no need to fast, avoid exercise, or worry about timing. A single sample, whether from blood or a cheek swab, gives you a permanent answer.
This also means that none of the confounders that complicate other lab results apply here. Acute illness, recent meals, medications, and time of day have no effect on your genotype result. If a lab reports your genotype, that result is definitive (assuming the genotyping was performed correctly, which modern assays do with very high accuracy).
This variant is one piece of a much larger picture. It is increasingly being incorporated into polygenic risk scores (calculations that combine the effects of hundreds or thousands of genetic variants to estimate your overall genetic predisposition to heart disease). A 2023 study found that people with borderline clinical risk whose polygenic risk score was high actually had event rates that crossed into the intermediate-risk category, which could justify earlier or more aggressive statin therapy.
On its own, a single variant like rs9349379 does not determine whether you will develop heart disease. But combined with your other genetic variants, lipid levels, inflammatory markers, imaging results, and family history, it provides a more complete picture of where your vascular vulnerabilities lie. For someone focused on prevention, knowing your genotype here helps you and your clinician decide which risks deserve the most attention and monitoring.
PHACTR1 Variant (rs9349379) is best interpreted alongside these tests.